Zobrazeno 61 - 70
of 153
pro vyhledávání: ''
Publikováno v:
Leukemialymphoma. 52(9)
The present study examined the clinical significance of serum neuron-specific enolase (NSE) in patients with diffuse large B-cell lymphoma (DLBCL). Serum NSE values were measured using a electrochemiluminescence assay in 106 patients and tissue NSE e
Publikováno v:
Leukemialymphoma. 52(12)
The management of "slow-go" patients with chronic lymphocytic leukemia (CLL) remains a primary unmet clinical need. This subgroup of patients, underrepresented in clinical trials, represents the burden of patients with CLL that will progressively inc
Autor:
Rossella Fabbricini, Fabro Pane, Giuseppe Ciancia, Guido Pettinato, Marco Picardi, Pio Zeppa, Ciro Mainolfi, Francesco Grimaldi
Publikováno v:
Leukemialymphoma. 52(11)
Because the lymphatic tissue of progressive transformation of germinal centers (PTGC) expresses CD20, rituximab treatment may prevent transformation to lymphoma of this rather atypical entity. We prospectively evaluated the efficacy of immunotherapy
Autor:
Seon Yang Park, Yeo Kyeoung Kim, Joo Seop Chung, Joon Seong Park, Sang Kyun Sohn, Hyeoung Joon Kim, Eunkyung Park, Ho In Kim, Ki Seong Eom, Moo Rim Park, Jinny Park, Joon Ho Moon, June-Won Cheong, Myung Soo Hyun, Sung-Soo Yoon, Hun Mo Ryoo, Min Kyoung Kim, Sukjoong Oh, Chul Soo Kim, Soo Mee Bang, Byung Soo Kim, Hawk Kim, Dong Hwan Kim, Chul Won Jung, Young Don Joo, Yoo Hong Min, Hong Ghi Lee, Deog Yeon Jo, Dae Young Zang, Jong Ho Won
Publikováno v:
Leukemialymphoma. 52(6)
To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or molecular responses, we measured trough IM levels in patients with chronic myeloid leukemia, chronic phase (CML-CP), at 6 months of treatment with a standard d
Autor:
Franck Morschhauser, Jack W. Singer, Raoul Herbrecht, Paul Cernohous, Peter Borchmann, Susan A. Veals, Georg Heß, Andreas Engert, Martin Wilhelm
Publikováno v:
Leukemialymphoma. 52(4)
Pixantrone is a potentially more effective, less cardiotoxic alternative to doxorubicin for patients with aggressive non-Hodgkin lymphoma (aNHL). This phase I/II non-comparative study evaluated pixantrone in place of doxorubicin in the standard CHOP
Autor:
John M. Brooks, Brian K. Link, X. Pan, Kara B. Wright, Elizabeth A. Chrischilles, Margaret D. Voelker
Publikováno v:
Leukemialymphoma. 52(6)
Anthracycline-based chemotherapy (ABC) is the most effective therapy for diffuse large B-cell lymphoma (DLBCL). The addition of rituximab to ABC in controlled trials has demonstrated superior survival, yet ABC is inconsistently utilized in elderly pa
Publikováno v:
Leukemialymphoma. 52(4)
A retrospective, population-based study was conducted to evaluate the incidence, clinical features, and outcome of malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH) in adults. Between January 1996 and December 2009, eight out of 887 (0
Autor:
Seok Jin Kim, Young Hyeh Ko, Jung A Kim, Do-Hyun Nam, Kihyun Kim, Won Seog Kim, In-Gu Do, Juyoun Jin
Publikováno v:
Leukemialymphoma. 52(2)
Hypoxia-associated proteins are commonly expressed as a consequence of disturbances in microcirculation. However, the clinical relevance of the proteins has never been studied in primary central nervous system lymphoma (PCNSL). The expression of hypo
Publikováno v:
Leukemialymphoma. 52(2)
The myelodysplastic syndromes (MDS) are a collection of hematologic disorders that affect older adults, and whose baseline characteristics and risk factors for evolution to acute myeloid leukemia (AML) and death have not been completely defined. We a
Publikováno v:
Leukemialymphoma. 51(12)
The treatment options for patients with myelodysplastic syndrome (MDS) who have failed DNA hypomethylating agents are limited. In this study, we set out to investigate the efficacy of low dose clofarabine in 10 patients with MDS (four intermediate-2/